Ergoteles’s Citius Pharmaceuticals CTXR Stock Holding History

Ergoteles’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,203	Closed	-$460K	–	1532
2022 Q3	$460K	Sell	15,203 -2,873	-16%	-$79K	0.02%	789
2022 Q2	$416K	Buy	+18,076	New	+$496K	0.01%	923

Other funds holding CTXR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ergoteles's CTXR Position: Q4 2022 in Review

Ergoteles sold out of Citius Pharmaceuticals (CTXR) in Q4 2022, closing a stake of 15,203 shares — an estimated $460K sold.

Ergoteles first reported a position in CTXR in Q2 2022 and held it in 2 quarters. The position peaked at $460K in Q3 2022. 54 funds tracked by Wall St. Rank hold CTXR as of Q4 2022.

Ergoteles reported no remaining Citius Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 15,203 Citius Pharmaceuticals shares in Q4 2022, an estimated $460K.
Ergoteles first reported a position in Citius Pharmaceuticals in Q2 2022 and held it in 2 quarters.
Ergoteles's Citius Pharmaceuticals position peaked at $460K in Q3 2022.
54 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.